Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Download PDF Copy

Jan 5 2016

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6^th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA. Dr. Karen L. Reckamp, Associate Professor at the City of Hope Comprehensive Cancer Center will present the poster titled "Phase l/ll trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)."

Session Information:
Date: January 6, 2016 12:30-2:30
Location: Encore, Abbey Road and Penny Lane rooms
Poster Number: B21

Source:

Xcovery

Posted in: Drug Trial News | Medical Condition News

Tags: B Cell, Cancer, Cell, Clinical Trial, Kinase, L.L., Lung Cancer, Lungs, Lymphoma, Neuroblastoma, Non-Small Cell Lung Cancer, Oncology, Small Cell Lung Cancer, T-Cell, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Study links air pollution to increased colorectal cancer risk through DNA changes

Study links air pollution to increased colorectal cancer risk through DNA changes

MONET: New AI tool enhances medical imaging with deep learning and text analysis

MONET: New AI tool enhances medical imaging with deep learning and text analysis

New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis

New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis

Study highlights how age affects nasal cell response to SARS-CoV-2

Study highlights how age affects nasal cell response to SARS-CoV-2

DASH diet may lower the risk of cardiovascular disease in breast cancer survivors

DASH diet may lower the risk of cardiovascular disease in breast cancer survivors

Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery

Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery

Breakthrough imaging method enhances precision in prostate cancer treatment

Breakthrough imaging method enhances precision in prostate cancer treatment

Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseases

Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New trials show promise for immune checkpoint blockers in early-stage lung cancer